Teva Pharmaceutical Industries - TEV Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€0.00
+0 (0.00%)

This chart shows the closing price for TEV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TEV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEV

Analyst Price Target is €0.00
This price target is based on 0 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €10,000,000.00. The average price target represents a NaN upside from the last price of €0.00.

This chart shows the closing price for TEV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Teva Pharmaceutical Industries. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/12/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/8/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/7/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/7/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/8/2019GMP SecuritiesReiterated RatingBuy$11.00
1/7/2019TD SecuritiesReiterated RatingBuy$10.00
(Data available from 12/7/2017 forward)

News Sentiment Rating

0.54 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 9 positive mentions
  • 3 negative mentions
  • 5 very negative mentions
5/11/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/10/2022
  • 6 very positive mentions
  • 8 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
7/10/2022
  • 6 very positive mentions
  • 20 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
8/9/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/8/2022
  • 8 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
10/8/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
11/7/2022
  • 7 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
12/7/2022

Current Sentiment

  • 7 very positive mentions
  • 4 positive mentions
  • 3 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Teva Pharmaceutical Industries logo
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Read More

Today's Range

Now: N/A

50 Day Range

MA: N/A

52 Week Range

Now: N/A

Volume

N/A

Average Volume

N/A

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

The following Wall Street research analysts have issued stock ratings on Teva Pharmaceutical Industries in the last year:
View the latest analyst ratings for TEV.

What is the current price target for Teva Pharmaceutical Industries?

0 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. has the lowest price target set, forecasting a price of €10,000,000.00 for Teva Pharmaceutical Industries in the next year.
View the latest price targets for TEV.

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for TEV.

What other companies compete with Teva Pharmaceutical Industries?

How do I contact Teva Pharmaceutical Industries' investor relations team?

The company's listed phone number is 972 3 914 8171. The official website for Teva Pharmaceutical Industries is www.tevapharm.com. Learn More about contacing Teva Pharmaceutical Industries investor relations.